GRAFTBIO IP – MGC PHARMA UPDATE

MGC Pharma, which uses Graft Polymer’s drug delivery platforms in relation to MGC Pharma’s CimetrA™ and CannEpil-IL™ products, confirmed that it has undertaken studies relating to the application of a base formulation nano delivery system, founded on the Company’s GraftBio IP, to improve the bioavailability of the active compounds using a non-invasive drug administration process. The study examined the toxicity of the base emulation to confirm its safety profile for potential use in future clinical research.

https://www.lse.co.uk/rns/GPL/graftbio-ip-8211-mgc-pharma-update-92bn776ufdur19t.html